Skip to content

Dexmedetomidine Sedation in Orthopedic Surgery

Prospective, Randomized Comparative Study of Intravenous Dexmedetomidine for Sedation in Orthopedic Surgery Under Regional Anesthesia

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04149626
Enrollment
60
Registered
2019-11-04
Start date
2020-01-29
Completion date
2022-06-30
Last updated
2020-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallux Valgus and Bunion, Sedation

Brief summary

60 patients ASA I-III, undergoing orthopedic surgery will be randomly assigned into one of three groups, namely group A (n=20), where dexmedetomidine will be used for sedation (initial bolus dose followed by continuous infusion), group B (n=20) where midazolam will be used for sedation (initial bolus dose followed by continuous infusion) and group C (n=20), where remifentanil will be used for sedation (initial bolus dose followed by continuous infusion). All patients will receive spinal anesthesia. Duration of postoperative analgesia, total dose of patient controlled IV morphine, sedation scores, nausea and vomiting, time of ambulation, sleep quality and patient satisfaction will be recorded for the first postoperative day. Additionally chronic pain on the site of surgery will be recorded in 3 and 6 months postoperatively.

Interventions

DRUGDexmedetomidine

Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)

DRUGMidazolam

Sedation using midazolam (initial bolus dose followed by continuous infusion)

DRUGRemifentanil

Sedation using remifentanil (initial bolus dose followed by continuous infusion)

Sponsors

Maria Tileli
CollaboratorUNKNOWN
Chryssoula Staikou
CollaboratorUNKNOWN
Asklepieion Voulas General Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Physical status according to American Society of Anesthesiologists (ASA) I-III Patients scheduled for orthopedic surgery

Exclusion criteria

Patient denial, contraindication of spinal anesthesia or any of the agents used in the protocol, BMI above 30, Serious psychiatric, mental and cognitive disorders, Language barrier, illicit substances abuse,

Design outcomes

Primary

MeasureTime frameDescription
Postoperative analgesia duration24 hoursTime of first demand for analgesia (PCA first bolus dose)

Secondary

MeasureTime frameDescription
Morphine consumption24 hoursDoses requested, morphine consumption in mg
Rescue analgesia24 hoursParacetamol in mg consumed
Sedation24 hoursRamsay Sedation Scale (numeric score from 1 to 6, based on responsiveness of the patient)
Postoperative pain: Numerical Rating Scale (NRS)24 hoursNumerical Rating Scale (NRS) scores (Range 0-10, 0=no pain, 10=the worse pain ever)
Delirium occurence24 hoursNu-DESK scale (presence of disorientation, inappropriate behavior, inappropriate communication,illusions/hallucinations, psychomoter retardation). Each of the 5 items is rated from 0 to 2. A total of 10 is the maximum score. A score of more than 2 identifies the presence of delirium.
Chronic pain: Graded Chronic Pain Scale (GCPS)6 monthsUsing of Graded Chronic Pain Scale (GCPS) Grade 0: No pain in prior 6 months Grade 1: Low Intensity - Low Disability Grade II: High Intensity Characteristic Pain Intensity - Low Disability Grade III: High Disability - Moderately Limiting Grade IV: High Disability - Severely Limiting
Complications24 hours

Countries

Greece

Contacts

Primary ContactAlexandros Makris, MD, MSc, PhD
makrisalexandros@hotmail.com+306947076446
Backup ContactMaria Tileli, MD
mtileli@gmail.com+306955258090

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026